Why Context Changes Everything
Here's where it gets nuanced: I'm skeptical of chronic melatonin for sleep, but I understand the appeal for serious disease.
The high-dose advocates aren't totally wrong about the science. At 10+ mg, melatonin shifts from circadian signaling to receptor-independent effects: direct antioxidant activity, mitochondrial protection, anti-inflammatory cascades. And there's genuinely interesting data for:
- Parkinson's: Motor improvements with 10-30 mg in meta-analyses
- Cancer: 20-40 mg alongside chemo reduces side effects, may improve survival
- ALS: Meaningful delays in animal models, ongoing human trials at 50-100 mg
The critical difference in risk-benefit calculation:
If you're facing progressive neurodegeneration or fighting cancer, a potential 90% increased heart failure risk in 30 years looks very different than if you're 35 and taking it for sleep. You're already managing complex treatments with significant risks. Quality of life improvements may be worth it.
But even then: This should be a conversation with your specialist (get multiple opinions), not based on internet forums. And we still don't have long-term safety data in any population.
What You Should Actually Do
If you're taking it for chronic insomnia:
❌ Probably time to reconsider, especially if:
- You've been on it 6+ months
- Your dose keeps creeping up
- You're over 65 or have cardiac risk factors
✅ Where it still makes sense:
- Short-term use (2-4 weeks) to reset sleep patterns
- Intermittent use for jet lag or shift work
- Specific circadian disorders
✅ Better alternatives to try for chronic insomnia:
- CBT-I (gold standard, more effective than melatonin)
- Sleep hygiene basics (consistent schedule, cool dark room, no screens 2 hours before bed)
- Rule out sleep apnea or other underlying disorders
If you're considering it for "anti-aging":
You're essentially self-experimenting based on rodent studies while we're seeing potential cardiovascular signals. Exercise and Mediterranean diet have exponentially more robust longevity data. If you proceed anyway, start low, track biomarkers closely, and have proper monitoring.
If you have Parkinson's, cancer, or ALS:
The calculation changes. Discuss with your specialist—this might be a reasonable risk-benefit trade-off for your situation. But get second opinions and monitor closely.
If you're over 65 with heart disease:
Be especially conservative. You're highest-risk for the 2025 preliminary findings. If you use it, keep it low-dose (≤3 mg), short-term, and discuss with your cardiologist.
Want to read the full breakdown? Check out the summary I wrote here.
|